These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 27609597

  • 1. In vitro susceptibility to mecillinam of Escherichia coli strains isolated from the urine of pregnant women.
    Duployez C, Loiez C, Cattoen C, Descamps D, Wallet F, Vachée A, Microbiologist Network from Nord-Pas-de-CalaisRéseau de microbiologistes du Nord-Pas-de-Calais, Nord-Pas-de-Calais, France..
    Med Mal Infect; 2016 Dec; 46(8):436-441. PubMed ID: 27609597
    [Abstract] [Full Text] [Related]

  • 2. Reversion of High-level Mecillinam Resistance to Susceptibility in Escherichia coli During Growth in Urine.
    Thulin E, Thulin M, Andersson DI.
    EBioMedicine; 2017 Sep; 23():111-118. PubMed ID: 28855073
    [Abstract] [Full Text] [Related]

  • 3. Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland.
    O'Kelly F, Kavanagh S, Manecksha R, Thornhill J, Fennell JP.
    BMC Infect Dis; 2016 Nov 03; 16(1):620. PubMed ID: 27806687
    [Abstract] [Full Text] [Related]

  • 4. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae.
    Raja NS.
    Int J Clin Pract; 2019 Sep 03; 73(9):1-5. PubMed ID: 31243859
    [Abstract] [Full Text] [Related]

  • 5. Pivmecillinam--therapy of choice for lower urinary tract infection.
    Graninger W.
    Int J Antimicrob Agents; 2003 Oct 03; 22 Suppl 2():73-8. PubMed ID: 14527775
    [Abstract] [Full Text] [Related]

  • 6. Clinical and bacteriological effects of pivmecillinam for ESBL-producing Escherichia coli or Klebsiella pneumoniae in urinary tract infections.
    Jansåker F, Frimodt-Møller N, Sjögren I, Dahl Knudsen J.
    J Antimicrob Chemother; 2014 Mar 03; 69(3):769-72. PubMed ID: 24107388
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Titelman E, Iversen A, Kalin M, Giske CG.
    Microb Drug Resist; 2012 Apr 03; 18(2):189-92. PubMed ID: 22204597
    [Abstract] [Full Text] [Related]

  • 8. Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient.
    Nielsen KL, Hansen KH, Nielsen JB, Knudsen JD, Schønning K, Frimodt-Møller N, Hertz FB, Jansåker F.
    Microbiologyopen; 2019 Dec 03; 8(12):e941. PubMed ID: 31573735
    [Abstract] [Full Text] [Related]

  • 9. Microbial risk factors for treatment failure of pivmecillinam in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
    Syre H, Hetland MAK, Bernhoff E, Bollestad M, Grude N, Simonsen GS, Löhr IH.
    APMIS; 2020 Mar 03; 128(3):232-241. PubMed ID: 31755584
    [Abstract] [Full Text] [Related]

  • 10. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S, Gençer S, Batırel A, Hacıseyitoğlu D, Ozer S.
    Mikrobiyol Bul; 2014 Oct 03; 48(4):545-55. PubMed ID: 25492650
    [Abstract] [Full Text] [Related]

  • 11. Results from a Prospective In Vitro Study on the Mecillinam (Amdinocillin) Susceptibility of Enterobacterales.
    Fuchs F, Hamprecht A.
    Antimicrob Agents Chemother; 2019 Apr 03; 63(4):. PubMed ID: 30917983
    [Abstract] [Full Text] [Related]

  • 12. Mecillinam/clavulanate combination: a possible option for the treatment of community-acquired uncomplicated urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G, Giamarellou H, Souli M.
    J Antimicrob Chemother; 2012 Oct 03; 67(10):2424-8. PubMed ID: 22665388
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
    Zykov IN, Frimodt-Møller N, Småbrekke L, Sundsfjord A, Samuelsen Ø.
    Int J Antimicrob Agents; 2020 Feb 03; 55(2):105851. PubMed ID: 31770624
    [Abstract] [Full Text] [Related]

  • 14. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
    Birgy A, Delecourt M, Geslain G, Desselas E, Caseris M, Magnan M, Mariani-Kurkdjian P, Bidet P, Bonacorsi S.
    J Antimicrob Chemother; 2017 Jul 01; 72(7):1911-1914. PubMed ID: 28369441
    [Abstract] [Full Text] [Related]

  • 15. High rate of per oral mecillinam treatment failure in community-acquired urinary tract infections caused by ESBL-producing Escherichia coli.
    Søraas A, Sundsfjord A, Jørgensen SB, Liestøl K, Jenum PA.
    PLoS One; 2014 Jul 01; 9(1):e85889. PubMed ID: 24454943
    [Abstract] [Full Text] [Related]

  • 16. Is it possible to extrapolate the rates of resistance of Escherichia coli from asymptomatic bacteriuria in pregnant women to those of E. coli in uncomplicated community-acquired UTI?
    Asenjo A, Grados MC, Oteo-Iglesias J, Alós JI.
    Rev Esp Quimioter; 2019 Aug 01; 32(4):375-378. PubMed ID: 31328907
    [Abstract] [Full Text] [Related]

  • 17. Synergistic and bactericidal activities of mecillinam, amoxicillin and clavulanic acid combinations against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in 24-h time-kill experiments.
    Skarp KP, Shams A, Montelin H, Lagerbäck P, Tängdén T.
    Int J Antimicrob Agents; 2019 Jan 01; 53(1):74-79. PubMed ID: 30236958
    [Abstract] [Full Text] [Related]

  • 18. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections.
    Azap OK, Arslan H, Serefhanoğlu K, Colakoğlu S, Erdoğan H, Timurkaynak F, Senger SS.
    Clin Microbiol Infect; 2010 Feb 01; 16(2):147-51. PubMed ID: 19689464
    [Abstract] [Full Text] [Related]

  • 19. Low frequency of antibiotic resistance among urine isolates of Escherichia coli in the community, despite a major hospital outbreak with Klebsiella pneumoniae producing CTX-M-15 in Uppsala County.
    Lindbäck H, Lindbäck J, Sylvan S, Melhus A.
    Scand J Infect Dis; 2010 Apr 01; 42(4):243-8. PubMed ID: 20085420
    [Abstract] [Full Text] [Related]

  • 20. [In-vitro activity of mecillinam against urine isolates of Escherichia coli from outpatient departments in Germany].
    Kresken M, Körber-Irrgang B, Naber KG.
    Aktuelle Urol; 2017 May 01; 48(3):243-247. PubMed ID: 28427111
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.